Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.
Intellia Therapeutics Announces Upcoming Investor Event To Present Interim Clinical Data From Ongoing First-In-Human Studies Of NTLA-2002 And NTLA-2001 On September 16
Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium
Event to include interim safety and serum TTR
